Methylene blue and ifosfamide-induced encephalopathy: Myth or reality? (2020)

Peer-Reviewed Study · Abahssain H, Moukafih B, Essangri H, Mrabti H, Meddah B, Guessous F, Fadhil FZ, Souadka A, Errihani H · November 5, 2020

Abahssain H et al., 2020-11-05: Moroccan single-centre series (four cases among 88 ifosfamide-treated patients) plus a 16-item literature review: 38 patients received methylene blue and 28 (75.6%) responded.

Overall, 38 (65.5%) patients received MB infusion and 28 (75.6%) patients responded favorably to the treatment.

Abahssain H et al., 2020-11-05: Moroccan single-centre series (four cases among 88 ifosfamide-treated patients) plus a 16-item literature review: 38 patients received methylene blue and 28 (75.6%) responded. C6. Study type: retrospective review plus literature review; National Institute of Oncology, Rabat, Morocco; period Sept 2016 – Sept 2017. N: 88 ifosfamide-treated patients, 4 with IIE (all received MB, 3 improved); literature review included 16 items covering 38 MB-treated patients. Dose not stated in the abstract text captured. Authors caution that methylene blue 'remains controversial' and that serotonergic syndrome must be watched for; call for prospective controlled trials. Funder/conflicts not stated in the PubMed record. J Oncol Pharm Pract 2021;27:143-149. Study type: uncontrolled series.